BIIB240823C210000
- 0.80
- +0.20+33.33%
Biogen Newsroom
Cracking The Code: Understanding Analyst Reviews For Biogen
Needham Maintains Biogen(BIIB.US) With Buy Rating, Maintains Target Price $285
Express News | Needham Reiterates Buy on Biogen, Maintains $285 Price Target
Optimistic Outlook for Biogen's Dapirolizumab Pegol Despite Past Setbacks
Biogen Enhances Financial Flexibility With New Credit Facility
Express News | Biogen - Revolving Credit Facility Includes Borrowing Capacity in Form of Letters of Credit of up to $25.0 Mln and $20.0 Mln in Swing Line Loans
Express News | Biogen - Credit Agreement Provides for a $1.5 Bln Five-Year Unsecured, Revolving Credit Facility
Express News | Biogen - on August 12, 2024, Entered Into a Credit Agreement
OpenFold AI Research Consortium Welcomes Six New Members: Astex, Biogen, Congruence, Polaris Quantum, Psivant, and SandboxAQ
"LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in the United Arab Emirates
Analysts Offer Insights on Healthcare Companies: Enanta Pharmaceuticals (ENTA), Hyperfine (HYPR) and Biogen (BIIB)
With 89% Institutional Ownership, Biogen Inc. (NASDAQ:BIIB) Is a Favorite Amongst the Big Guns
How Is The Market Feeling About Biogen?
As Traumatic Brain Injuries Increase, Global Concussion Market Size Expected to Reach $10 Billion By 2032
Investors Can Find Comfort In Biogen's (NASDAQ:BIIB) Earnings Quality
Guolian Securities: Increased attention to tumor immunology, recommend focusing on targeted drugs such as PD1/IL2 in pharmaceutical companies.
With the increasing attention to tumor immunity, and the successive launch of advantageous products, bullish on PD1/IL2 and PD1/IL15 targeted drugs.
Mizuho Securities Maintains Biogen(BIIB.US) With Buy Rating, Cuts Target Price to $251
Mizuho Maintains Outperform on Biogen, Lowers Price Target to $251
Express News | Biogen : Canaccord Genuity Cuts Target Price to $298 From $308
Express News | Biogen : Mizuho Cuts Target Price to $251 From $277